Continuing on its upward and fast-paced trajectory, Pieris Pharmaceuticals (Nasdaq: PIRS), today has entered into a collaboration and license agreement with Seattle Genetics (Nasdaq: SGEN) with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers.
Under the terms of the accord, Seattle Genetics will pay Pieris a $30 million upfront fee, tiered royalties on net sales up to low double-digits, and up to $1.2 billion in total success-based payments across three product candidates.
News of the deal saw Pieris’ shares jump 11.84% to $8.00 by around midday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze